Allo-QuadCAR01-T

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAllo-QuadCAR01-T

Drug Alias NameAllo-QuadCAR01-TAVC-203

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy +[4]

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermany

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAvenCell Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAvenCell Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphomaLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A